No significant differences in the median age at disease onset (median 49.5 years versus median 49.0 years) or the median disease duration at the time of analysis (median 15.0 years vs. median 16.0 years) were observed between RA patients positive or negative for the CCR5 d32 deletion. This evidence concerns the gene CCR5 and rheumatoid arthritis.